Navigation Links
Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
Date:9/17/2012

BERLIN, Sept. 17, 2012 /PRNewswire/ -- Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, presented Phase 2 clinical data of JX-594 delivered first intravenously and subsequently through intra-tumoral route demonstrating safety as well as disease control and tumor responses in patients with hepatocellular carcinoma (liver cancer, HCC).  The data were presented in an oral presentation at the International Liver Cancer Association (ILCA) Annual Meeting in Berlin, Germany, by Mong Cho, M.D., from Pusan National University Yangsan Hospital, South Korea.

Twenty five Asian patients with advanced HCC, 20 of whom were refractory to sorafenib, were treated with an initial intravenous dose of JX-594, and the majority of patients then received sequential intra-tumoral doses of JX-594 at week one and three. The majority of patients subsequently received treatment with sorafenib.

The primary objective of this study was to determine the safety of JX-594 followed by sorafenib in patients with advanced HCC. The sequential treatment regimen was well tolerated with transient flu-like symptoms and transient leukopenia being the most common side effects related to JX-594.  The sorafenib side effects observed were consistent with the expected toxicity profile of this product.

Secondary endpoints included the effect of the sequential treatment of JX-594 followed by sorafenib on disease control and tumor response. Evidence of antitumor activity was observed in both sorafenib-naive and sorafenib-refractory patients. 

Importantly, this trial also demonstrated the feasibility of the systemic administration of the product (through intravenous injection).

"Our ability to deliver JX-594 intravenously to liver cancer tumors, further confirmed by these encouraging data, is a key attribute that sets it apart from other thera
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
2. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
3. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
4. Mettler Toledo Presents In-depth Guidance to Comply with New USP Chapters 41 and 1251 on Balances Used for Quantitative Analysis in the Pharma QC Lab
5. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
6. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
7. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
8. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
9. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
10. Grant & Eisenhofer Represents Key Whistleblower in Justice Dept.s $1.04 Billion Civil Settlement with GlaxoSmithKline
11. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company plc ... the Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder ... "Our views of Mylan,s offer to Perrigo ... based on our Board,s careful reflection of the value ... the limited choices that Mylan has allowed its shareholders ...
(Date:8/28/2015)... , Aug. 28, 2015 ... and Dr. Ra from Biostar , Published in ... 30% increase of lifespan through multiple IV administration of ... vitality, and life expectancy found , Commercialization within ... have determined the possibility that adult mesenchymal stem cells ...
(Date:8/28/2015)... FRANCISCO , August 28, 2015 ... expected to reach USD 49.12 billion by 2020, growing ... according to a new report by Grand View Research, ... estimated CAGR of 49.7% from 2014 to 2020. ... Growing aging population along with rising incidences of chronic ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5
... 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in development ... inihibtors have been validated to show survival benefits in cancer ... in combination with DNA damaging agents, and BMN 673 appears ...
... 2011 Virtual Radiologic (vRad), a technology-enabled national radiology ... the Teleradiology Services market segment by independent research and ... customer surveys and interviews conducted by KLAS and is ... in KLAS Awards: Software & Professional Services report. ...
Cached Medicine Technology:BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 2BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 3Virtual Radiologic Ranked #1 for Teleradiology Services for Third Consecutive Year 2
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of the ... and good people, all for a good cause. In its second year, the “Music ... more by Best Drug Rehabilitation. The “Mission” of “Music With A Mission” is to ...
(Date:8/28/2015)... ... 28, 2015 , ... Healthpointe clinics throughout Southern California ... diving. The act of recreational diving exposes the body to extreme changes ... vital that all recreational and professional divers undergo regular comprehensive scuba physicals. Healthpointe’s ...
(Date:8/28/2015)... ... August 28, 2015 , ... The newest therapy to receive orphan drug status ... any time soon, according to educational website Surviving Mesothelioma. Click here to read ... designation for mesothelioma last week from the FDA, will now head into Phase I ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... is pleased to welcome TJS Insurance Group as its newest Partner Firm. Founded ... guides them and keeps them focused on their goals. Within the past 10 ...
(Date:8/28/2015)... ... August 28, 2015 , ... External Counterpulsation, also known ... Clinic is now selling External Counterpulsation (EECP or ECP) machines with a full clinic ... has been in business since 2007 helping people prevent and reverse heart disease ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2
... savings comes an extra,hour of sleep, but how ... to the daily cup of coffee, early birds ... the Flower Promotion Organization at:, http://media.medialink.com/WebNR.aspx?story=34055 ) ... that study participants reported being happier and more ...
... Stryker Corporation,(NYSE: SYK ) announced today that it will participate in the ... 8:30 a.m. Mountain Standard Time Credit ... November 27, 2007 - 12:30 p.m. ... Care Conference New York, New York ...
... University Class Tests Benefits of Chewing Gum During Exam, ... can,be particularly stressful on college students as they struggle ... (Photo: http://www.newscom.com/cgi-bin/prnh/20071101/AQTH193 ) "It,s common practice ... and pull all-nighters in preparation for exams," says Adrinda,Kelly, ...
... Centers, Inc.,("GNC" or the "Company"), announced today that it ... third quarter 2007 financial,results at 11 a.m. EST Thursday, ... the U.S., dial 1-888-895-5479, and,outside the U.S. dial 1-847-619-6250. ... webcast of the call will also be available,through the ...
... awards,Ashaway,s horse-assisted rehabilitative therapy with Premier Center Program ... ... Nov. 1 Turning Pointe,Therapeutic Riding has again been recognized ... the Handicapped Association (NARHA),the national standard bearer for therapeutic equine ...
... Kids,Indiana Action Fund launched an independent, direct ... supporting local elected officials who,have championed smoke-free ... - D) and Scott Keller (District 16 ... in passing Indianapolis, smoke-free,ordinance. The Indianapolis smoke-free ...
Cached Medicine News:Health News:Stryker to Present at Investor Conferences 2Health News:As Exams Loom, Students Find Hope in a 'Stick' 2Health News:As Exams Loom, Students Find Hope in a 'Stick' 3Health News:As Exams Loom, Students Find Hope in a 'Stick' 4Health News:Turning Pointe Therapeutic Riding Recognized for Excellence in Providing Equine-Assisted Therapies to People with Disabilities 2Health News:Tobacco-Free Kids Indiana Action Fund Launches Campaign in Support of Angela Mansfield and Scott Keller for Indianapolis City-County Council 2Health News:Tobacco-Free Kids Indiana Action Fund Launches Campaign in Support of Angela Mansfield and Scott Keller for Indianapolis City-County Council 3
10 mm angled blade with notches on sides and tip. Round knurled handle with polished finish....
1 mm wide by 33 mm long malleable blade. Flat serrated handle with polished finish....
Lasik spatula useful for protecting a previous flap for retreatment to lift and smooth the corneal flap....
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 130o....
Medicine Products: